STOCKS TELEGRAPH

Tag: NASDAQ:LFWD

  • FDA Approval of ReWalk 7 Sends Lifeward (LFWD) Stock Climbing

    FDA Approval of ReWalk 7 Sends Lifeward (LFWD) Stock Climbing

    The most recent regulatory accomplishment of Lifeward Ltd. (NASDAQ: LFWD) is causing its shares to increase 68.03% to $2.47 as of today’s latest check. The price surge followed a regulatory go ahead for its newest product, the ReWalk 7 personal exoskeleton. This achievement marks a turning point in the company’s history and demonstrates its commitment to creating medical technology for those with spinal cord injuries (SCI).

    The ReWalk 7 Exoskeleton Received FDA approval

    With the FDA’s 510(k) certification of Lifeward’s ReWalk 7, wearable exoskeleton technology has advanced significantly. The latest version of the ReWalk has been enhanced with features designed to help persons with SCI stand and walk again. With cutting-edge upgrades and improvements, the ReWalk 7 builds on the technology that has already transformed lives by giving users more comfort and utility.

    A Major Advancement for the Industry

    For almost two decades, Lifeward has been at the forefront of exoskeleton innovation. The FDA approval of ReWalk 7 is a victory for both Lifeward and the medical community at large. LFWD’s continuous advancement in offering cutting-edge mobility solutions shows how committed it is to improving the lives of people with SCI. Lifeward is still committed to developing and enhancing these vital technologies in novel ways.

    Growth and Strategic Alliances

    Apart from the approval of the ReWalk 7, Lifeward has advanced in broadening its scope. To become the only distributor of the ReWalk Personal Exoskeleton for those with Workers’ Compensation claims, LFWD has reached a deal with CorLife, LLC, a Numotion subsidiary. This collaboration will make use of CorLife’s extensive provider and expert network, guaranteeing that more people have access to this transformative technology and expediting the claims procedure. By promoting growth and increasing possibilities for SCI patients nationwide, Lifeward maintains its position as a pioneer in the industry.

  • Lifeward (LFWD) Shares Continue Momentum In Pre-Hour Surge

    Lifeward (LFWD) Shares Continue Momentum In Pre-Hour Surge

    Lifeward Ltd. (NASDAQ: LFWD) is extending its upward momentum in today’s trading session, continuing a sharp rally from the previous day. After a strong 33.57% increase the previous session, when it ended at $1.87, LFWD stock has risen 10.64% to $2.07 as of the most recent premarket check. The company’s recent historic deal with one of Germany’s top health insurers is a major factor in this positive trend.

    Strategic Partnership with BARMER

    A significant contract between Lifeward and BARMER, the second-largest statutory health insurance provider in Germany, was formally concluded last week. For medically approved clients, the contract creates a systematic reimbursement procedure for ReWalk Exoskeletons, a vital assistive device for people with spinal cord injuries.

    This agreement streamlines access for insured individuals while reinforcing BARMER’s leadership in the German healthcare sector. Furthermore, it establishes a standard for the wider implementation of exoskeleton insurance coverage, both in Germany and internationally. The collaboration is an important step in expanding access to mobility solutions that improve people’s lives, especially as Lifeward continues to expand into reimbursement programs.

    Growing International Insurance Coverage

    Over the past year, Lifeward has seen notable progress in insurance reimbursement policies across multiple regions. The company has secured Medicare coverage in the United States, state-backed insurance in Hungary, and now an influential agreement with BARMER in Germany. These developments position Lifeward favorably for further expansion, particularly as it pursues approvals from Medicare Advantage Programs and various commercial insurers in the U.S.

    BARMER, which insures more than 8.5 million beneficiaries, has already provided 20 ReWalk Personal Exoskeletons to eligible individuals in recent years. The newly established contract formalizes reimbursement procedures, ensuring that medically qualified beneficiaries can access these devices for daily use under clearly defined conditions.

    Upcoming Investor Event and Product Showcase

    In addition to this milestone agreement, Lifeward has announced a virtual Investor Event scheduled for next Thursday. Presentations from the company’s executive leadership team will be given throughout the event, offering information on Lifeward’s financial outlook, major initiatives, and strategic direction.

    Innovations from Lifeward’s product line, such as the AlterG Anti-Gravity System and the ReWalk Exoskeleton, which are both regarded as industry-leading treatments for neurological and orthopedic disorders, will also be on display during the event.